Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal
Mandate

Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal

February 17, 2011

As a part of the ongoing privatisation of the terminal operations in the Port of Gothenburg, the car terminal has been transferred to Logent AB. At the same time, a 10-year licence agreement has been entered into between the parties regarding utilisation of the terminal and related infrastructure. The Port of Gothenburg is the largest port in the Nordic region and a focal point for the Swedish car industry. Logent AB is a Swedish company with approximately 1000 employees which conducts ports, combined terminals and warehousing operations in Sweden and Norway. Vinge advised the Port of Gothenburg Harbour during the privatisation procedure.
Vinge’s team consisted of, among others, Fredrik Sonander, Charlotte Johansson and Lisa Askbrink.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026